Table II.
Clinical features
| Item | Total | Abrocitinib | Baricitinib | Ritlecitinib | Upadacitinib | Tofacitinib |
|---|---|---|---|---|---|---|
| Total, n | 72 | 8 | 27 | 6 | 15 | 16 |
| Age of onset (median, IQR) | 23 (21) | 30 (15) | 31 (24) | 17 (21) | 15 (17) | 19 (24) |
| Years of disease duration, mean (SD) | 8.7 (8.0) | 8.8 (6.42) | 10.2 (9.8) | 13.6 (9.1) | 5.3 (6.1) | 6.3 (4.0) |
| Baseline Severity of Alopecia Tool (median, IQR) | 100 (10) | 100 (14) | 100 (3) | 100 (10) | 98 (47) | 100 (26) |
| Type of alopecia areata, n (%) | ||||||
| Alopecia areata patchy type | 21 (29.2%) | 2 | 5 | 1 | 7 | 6 |
| Alopecia totalis | 11 (15.3%) | 1 | 5 | 1 | 4 | 0 |
| Alopecia universalis | 39 (54.2%) | 5 | 16 | 4 | 4 | 10 |
| Alopecia areata ophiasis type | 1 (1.4%) | 0 | 1 | 0 | 0 | 0 |
| Other localization, n (%) | ||||||
| Eyebrows | 48 (66.7%) | 5 | 19 | 5 | 6 | 13 |
| Eyelashes | 45 (62.5%) | 5 | 17 | 5 | 6 | 12 |
| Beard | 14 (19.4%) | 0 | 3 | 2 | 2 | 7 |
| Body hair | 34 (47.2%) | 5 | 14 | 3 | 3 | 9 |
| Nail changes, n (%) | 11 (15.3 %) | 0 | 3 | 1 | 2 | 5 |
| Months of follow-up, mean (SD) | 15.7 (14.7) | 8.4(7.2) | 14.6 (14.3) | 12.4 (16.6) | 12.3 (8.2) | 26.4 (18.7) |